Common Plant Compound Shields Testes From Chemotherapy Damage in Rat Study

Cisplatin is one of the most effective and widely used chemotherapy drugs in the world, credited with saving countless lives from testicular, ovarian, bladder and lung cancers. Yet its reputation comes with a heavy caveat: the same reactivity that makes cisplatin lethal to tumor cells also makes it destructive to healthy tissue, and the testes are among its most vulnerable targets. Men treated with the drug frequently experience lasting damage to sperm production and hormone balance, sometimes resulting in permanent infertility. Now a team of researchers in Türkiye reports that a humble plant-derived molecule, protocatechuic acid, may offer a way to shield the testes from this collateral harm, and their new study maps the molecular machinery behind that protection in unusually fine detail.

The research, led by Huseyin Yaman and Selim Demir of the Department of Medical Biochemistry at Karadeniz Technical University in Trabzon, together with colleagues at Recep Tayyip Erdogan University, was published in BMC Complementary Medicine and Therapies. Protocatechuic acid, often abbreviated PCA, is a phenolic compound found naturally in many foods, including olives, blueberries, plums and onions, and it is also generated in the human body when larger plant polyphenols are broken down during digestion. Because it is small, readily absorbed and known to carry antioxidant activity, PCA has drawn growing interest as a possible chemopreventive agent, a compound that could be given alongside toxic drugs to protect normal tissues without weakening the anticancer effect.

To test that idea rigorously, the researchers designed a controlled experiment involving thirty adult male rats divided into five groups. One group served as a sham control, receiving no toxic challenge. A second group received protocatechuic acid alone at a dose of 100 milligrams per kilogram of body weight, to establish whether the compound had any harmful effects of its own. A third group received cisplatin at 7.5 milligrams per kilogram, delivered as a single intraperitoneal injection on the second day of the experiment, a dose calibrated to reproduce the kind of oxidative testicular injury seen clinically. The final two groups received cisplatin followed by oral protocatechuic acid at either 50 or 100 milligrams per kilogram, administered daily for seven days. This design allowed the team to compare the damage caused by cisplatin with the degree of rescue produced by two different strengths of the protective compound.

The results were striking. Cisplatin administration devastated the antioxidant defenses of the testes, producing severe lipid peroxidation, the chain-reaction destruction of the fatty membranes that surround sperm-producing cells. The researchers traced this collapse to a dramatic suppression of two master regulators of cellular redox balance: sirtuin 1, known as SIRT1, and nuclear factor erythroid 2-related factor 2, known as Nrf2. SIRT1 is a longevity-associated enzyme that maintains cellular health under stress, while Nrf2 is the transcription factor that switches on the cell’s antioxidant arsenal, including enzymes such as superoxide dismutase, glutathione peroxidase and the glutamate-cysteine ligase catalytic subunit that replenishes glutathione, the tissue’s principal internal antioxidant. When cisplatin silenced this SIRT1-Nrf2 axis, the testicular tissue was left essentially disarmed against the flood of reactive oxygen species the drug unleashes.

The damage did not stop at oxidation. The study showed that cisplatin also activated the nuclear factor kappa B pathway, a central inflammatory switch, which in turn drove elevated production of interleukin-6, a pro-inflammatory signaling molecule. At the same time, the drug triggered endoplasmic reticulum stress, a state in which the cellular organelle responsible for folding proteins becomes overwhelmed and initiates an unfolded protein response. Markers of this stress response, including binding immunoglobulin protein, activating transcription factor 6 and growth arrest and DNA damage-inducible gene 153, rose in the cisplatin-treated tissue. The final consequence was apoptosis, the programmed death of cells, confirmed both by biochemical measures of cleaved caspase-3, the executioner enzyme of cell death, and by TUNEL staining that revealed widespread DNA fragmentation in the seminiferous tubules.

Under the microscope, the toll on fertility was unmistakable. Histopathological examination using hematoxylin and eosin staining showed disorganized, damaged seminiferous tubules, the structures in which sperm are produced. Johnsen tubular biopsy scoring, a standard histological measure of testicular health, fell sharply in the cisplatin group, as did inhibin B, a hormone produced by support cells in the testes that serves as a sensitive marker of sperm-producing capacity, alongside measurable changes in testosterone. An elevated apoptotic index confirmed that a large fraction of the germ cells was dying. Together, these findings painted a complete picture of chemotherapy-induced testicular toxicity spanning oxidation, inflammation, protein-folding stress and cell death.

Protocatechuic acid reversed this cascade on nearly every front. In the rats that received the compound alongside cisplatin, the researchers documented significant improvements in oxidative stress markers, with restoration of antioxidant enzyme activity and reductions in malondialdehyde, myeloperoxidase and total oxidant status. The inflammatory NF-κB/interleukin-6 axis quieted, endoplasmic reticulum stress markers declined, and apoptotic cell death fell substantially. Most tellingly, PCA lifted the cisplatin-induced suppression of SIRT1 and Nrf2, suggesting that the compound works at least in part by reactivating the very signaling hub that chemotherapy had knocked out. Histopathology told the same story from a different angle: testicular architecture was better preserved, tubular scores improved, and TUNEL staining revealed far fewer dying cells. Both the 50 and 100 milligram per kilogram doses were effective, and the compound alone caused no observable harm.

The mechanistic story matters because it distinguishes this work from earlier, simpler antioxidant studies. Many compounds can mop up free radicals in a test tube, but the authors argue that PCA’s value lies in its modulation of upstream regulatory pathways: by preserving SIRT1 activity and allowing Nrf2 to escape repression by its inhibitor Keap1, the compound helps the tissue rebuild its own defenses rather than merely borrowing an external one. This layered action, spanning antioxidant, anti-inflammatory and anti-apoptotic arms simultaneously, is precisely what makes a candidate chemopreventive agent attractive for clinical translation, since chemotherapy toxicity is never a single-pathway problem.

The researchers emphasize that theirs is the first study to demonstrate this protective effect of protocatechuic acid against cisplatin-induced testicular toxicity, and they hypothesize that the molecule could eventually become a promising chemopreventive option for male patients undergoing cisplatin treatment, potentially preserving fertility in young cancer survivors for whom this is a lifelong concern. The team also points to the practical advantages of PCA: it is inexpensive, naturally available, orally bioavailable and already consumed safely in the diet. Still, the usual caveats apply. The findings come from a rat model with a short treatment window, and no clinical trial has yet tested PCA in human patients receiving chemotherapy. Dose, timing and possible interactions with cisplatin’s anticancer activity, a critical concern for any protective co-treatment, will all need careful evaluation before the compound can move from the laboratory bench to the oncology ward. The work was approved by the Local Animal Research Ethics Committee of Karadeniz Technical University and conducted under international animal research guidelines, and the authors declare no competing interests. As fertility preservation becomes an increasingly prominent part of cancer care, especially for adolescents and young men, simple dietary molecules that can be deployed to protect the gonads without compromising tumor treatment represent one of the most hopeful directions in supportive oncology, and this study offers a detailed molecular roadmap for exactly that ambition.

Subject of Research: Protective effects of protocatechuic acid against cisplatin-induced oxidative testicular injury in rats through modulation of redox homeostasis.

Article Title: Protocatechuic acid counteracts cisplatin-induced oxidative testicular injury in rats through modulation of redox homeostasis

Article References: Protocatechuic acid counteracts cisplatin-induced oxidative testicular injury in rats through modulation of redox homeostasis. (n.d.). https://doi.org/10.1186/s12906-026-05604-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05604-y

Keywords: protocatechuic acid, cisplatin, testicular toxicity, oxidative stress, SIRT1, Nrf2, NF-κB, endoplasmic reticulum stress, apoptosis, chemoprevention, infertility, rat study